Literature DB >> 18047914

Prevalence and persistence of masked hypertension in treated hypertensive patients.

Willem J Verberk1, Theo Thien, Abraham A Kroon, Jacques W M Lenders, Gert A van Montfrans, Andries J Smit, Peter W de Leeuw.   

Abstract

BACKGROUND: Masked hypertension (MH) is defined as a normal blood pressure in the physician's office and an elevated blood pressure when measured out-of-office. The cause of MH may be termed the masked hypertension effect (MHE), and is not restricted to blood-pressure (BP) values around the thresholds for normal BP. We investigated the prevalence and persistence of MH and MHE in patients who were being treated for high BP and who had been followed for a period of 1 year.
METHODS: One hundred and sixty-one treated hypertensive patients underwent office blood-pressure measurements (OBPMs) at seven visits and self-performed blood-pressure measurements (SBPMs) for 1 week before each visit over a period of 1 year. All measurements were performed with the same type of automatic device. At each visit, MH was determined according to the European Society of Hypertension definition (OBPM, <140/90 mm Hg; SBPM, >/=135 mm Hg or 85 mm Hg). In addition, we determined prevalences of MHE at 5/3 mm Hg (SBPM exceeds OBPM by 5 mm Hg systolic and 3 mm Hg diastolic), and MHE at 10/6 mm Hg (SBPM exceeds OBPM by 10 mm Hg systolic and 6 mm Hg diastolic), respectively.
RESULTS: During the entire study, 50% of the patients had MH, and 40% had MHE at 5/3 mm Hg at least once. At four sequential OBPM visits, 2% consistently had MH, and 3% had MHE at 5/3 mm Hg or MHE at 10/6 mm Hg. The prevalence of MH increased with lower OBPM levels but remained rather constant for MHE at 5/3 mm Hg and MHE at 10/6 mm Hg. The persistence of MH and the MHE over time in individual patients was low.
CONCLUSIONS: We conclude that MH and MHE at 5/3 mm Hg and MHE at 10/6 mm Hg commonly occur in treated patients, but are not persistent phenomena and probably result from an accidentally low OBPM value on one particular occasion.

Entities:  

Mesh:

Year:  2007        PMID: 18047914     DOI: 10.1016/j.amjhyper.2007.08.002

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Hypertension and Diabetes Prevalence in Older Persons in Jamaica, 2012.

Authors:  K Mitchell-Fearon; N Waldron; K James; H Laws; D Holder-Nevins; D Eldemire-Shearer
Journal:  West Indian Med J       Date:  2014-08-14       Impact factor: 0.171

2.  Reproducibility of masked uncontrolled hypertension detected through home blood pressure monitoring.

Authors:  Jessica Barochiner; María Lourdes Posadas Martínez; Rocío Martínez; Diego Giunta
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-19       Impact factor: 3.738

3.  Persistence and progression of masked hypertension: a 5-year prospective study.

Authors:  Xavier Trudel; Alain Milot; Chantal Brisson
Journal:  Int J Hypertens       Date:  2013-12-17       Impact factor: 2.420

Review 4.  Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis.

Authors:  Katherine L Tucker; James P Sheppard; Richard Stevens; Hayden B Bosworth; Alfred Bove; Emma P Bray; Kenneth Earle; Johnson George; Marshall Godwin; Beverly B Green; Paul Hebert; F D Richard Hobbs; Ilkka Kantola; Sally M Kerry; Alfonso Leiva; David J Magid; Jonathan Mant; Karen L Margolis; Brian McKinstry; Mary Ann McLaughlin; Stefano Omboni; Olugbenga Ogedegbe; Gianfranco Parati; Nashat Qamar; Bahman P Tabaei; Juha Varis; Willem J Verberk; Bonnie J Wakefield; Richard J McManus
Journal:  PLoS Med       Date:  2017-09-19       Impact factor: 11.069

5.  Self-monitoring of Blood Pressure in Patients With Hypertension-Related Multi-morbidity: Systematic Review and Individual Patient Data Meta-analysis.

Authors:  J P Sheppard; K L Tucker; W J Davison; R Stevens; W Aekplakorn; H B Bosworth; A Bove; K Earle; M Godwin; B B Green; P Hebert; C Heneghan; N Hill; F D R Hobbs; I Kantola; S M Kerry; A Leiva; D J Magid; J Mant; K L Margolis; B McKinstry; M A McLaughlin; K McNamara; S Omboni; O Ogedegbe; G Parati; J Varis; W J Verberk; B J Wakefield; R J McManus
Journal:  Am J Hypertens       Date:  2020-03-13       Impact factor: 2.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.